echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The status quo of pulmonary fibrosis treatment in the post-epidemic era is at a glance

    The status quo of pulmonary fibrosis treatment in the post-epidemic era is at a glance

    • Last Update: 2020-10-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The new crown pneumonia (COVID-19), which is currently ravaging the world, is largely under control at home, but the battle is far from over.
    post-epidemic era, the legacy of the new crown should be paid enough attention to.
    COVID-19 virus and the 2003 SARS virus belong to the coronavirus β genus, both viruses have more than 70% similarity in gene sequence, and there are many similarities in clinical symptoms.
    follow-up study of SARS patients found that lung damage in severe SARS patients was likely to be irreversible, leaving behind symptoms of pulmonary fibrosis.
    there have been several cases of new coronary pneumonia reported to have pulmonary fibrosis after rehabilitation, and no statistically significant studies have confirmed a direct link between COVID-19 infection and pulmonary fibrosis.
    addition to pulmonary fibrosis, patients with neocyctic pneumonia have also been reported to have symptoms such as fatigue, bloating, headaches and so on.
    pulmonary fibrosis attract widespread attention? Idiopathic pulmonary fibrosis (IPF) is a major lung disease characterized by the proliferation of fibroblasts and the accumulation of large amounts of extracellular substrates accompanied by inflammatory damage and tissue damage.
    the IPF is irreversible and has a very poor prognostosm, with a five-year survival rate of less than 30%.
    current treatment can not achieve the goal of cure, can only delay the progress of the disease and improve the quality of life of patients.
    incidence increased, while limited treatment methods IPF is more common in middle-aged and elderly men, the incidence rate is not significantly different.
    in recent years, the incidence rate has been increasing year by year.
    pathogenesis of the disease is not clear, suspicion and genetic factors.
    5-year survival rate of IPF is less than 30%, which is even lower than that of some cancers.
    currently, the antifibrosis drugs recommended by the treatment guidelines are nidanib and pyridoxine, neither of which can cure IPF and only slow the progression of the disease.
    in addition to glucosticoid drugs, immunosuppressant drugs, antioxidant drugs, oxygen therapy, etc. are also used in the treatment of IPF.
    lung transplants may be required in patients who are progressing to the end of the period.
    is the world's first drug to be marketed for IPF, originally developed by Marnac of the United States, and in April 1997, Japan's Yanoyi Pharmaceuticals won the right to develop it in Japan, South Korea and Taiwan.
    was approved for treatment with IPF in Japan in 2008, became the first treatment approved for light to moderate IPF in adults in the European Union in 2011, and in August 2014 Roche Pharmaceuticals obtained global rights to pyridoxine and was approved by the FDA for treatment of IPF in October 2014.
    domestic market is dominated by Athray of Cantini Pharmaceuticals, which was approved in 2011 as the first new class of drugs approved in China for the treatment of mild to moderate IPF.
    , developed by Bringer Ingham and approved in the United States in October 2014, is the first FDA-approved tyrosine kinase inhibitor to treat IPF and was approved domestically in 2017.
    in the study of products IF market demand is broad, and the existing treatment methods can not meet the demand well.
    Insight database shows that the current clinical phase of IPF in the study of new drugs as follows: (data as of October 20, 2020) from: Insight database () East Sunshine Pharmaceuticals East Sunshine Pharmaceuticals, a class of innovative drug espoloride was approved in China in March 2017, in August 2017 has been approved by the FDA orphan drug, has now completed clinical phase I trials in the United States.
    clinical trials have shown that the activity of estrogen is significantly superior to that of pyridone, a class of potential me better drugs for pyridone.
    jacphedrinib hydrochloride, a class of innovative drugs, was approved in China in January 2020 as the first JAK inhibitor-type drug to be approved for clinical use in the treatment of IPF.
    hydrochloric acid has previously been licensed for clinical trials of four adaptations: bone marrow fibrosis, severe baldness, rheumatoid arthritis and severe spina bifitis.
    ZSP1603, a class of innovative drugs in the pharmaceutical industry, was approved in China in October 2017, and is the first small molecule innovation drug approved for clinical treatment of IPF and malignancies at the same target in China.
    preclinical data show that ZSP1603 has better anti-pulmonary fibrosis than Nidanib and is safe to use.
    YPS345, an innovative drug of Tianfang Pharmaceuticals, was approved in China in January 2019 for the treatment of pneumonia and pulmonary fibrosis caused by chest radiation therapy in tumor patients.
    clinical trials showed significant relief effects on pulmonary fibrosis induced by chemotherapy, and the safety was good.
    , which is based in Henrui Pharmaceuticals, was approved for clinical use in the treatment of IPF in November 2015.
    methionine as a multi-target tyrosine kinase inhibitor, and has also been approved for clinical trials in a variety of cancer species.
    References: He Xiaoyun, Hou Yijun, Qin Fang, Zhang Nan, Li Jing, Zhou Yunzhi, Guo Wei. Severe SARS Chinese and Western medicine combined with the treatment of recovering patients after 2 and a half years of lung function change analysis. World Science and Technology (modernization of Chinese medicine), 2011, 13 (02): 253-258.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.